{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T21:06:15Z","timestamp":1770066375260,"version":"3.49.0"},"reference-count":36,"publisher":"Japanese Society of Hypertension","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2005]]},"DOI":"10.1291\/hypres.28.431","type":"journal-article","created":{"date-parts":[[2006,2,9]],"date-time":"2006-02-09T05:56:55Z","timestamp":1139464615000},"page":"431-438","source":"Crossref","is-referenced-by-count":24,"title":["Nifedipine Enhances the Cardioprotective Effect of an Angiotensin-II Receptor Blocker in an Experimental Animal Model of Heart Failure"],"prefix":"10.1291","volume":"28","author":[{"given":"Nobuaki","family":"OKUDA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"HAYASHI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuhiko","family":"MORI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakiko","family":"INAMOTO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"OKABE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigetoshi","family":"MIENO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"HORIMOTO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"KITAURA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"119","reference":[{"key":"1","unstructured":"1. Havranek EP, Abraham WT: The health care economics of heart failure. <i>Heart Failure<\/i> 1998; <b>14<\/b>: 10-18."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. McMurray JJ, Stewart S: Epidemiology, aetiology, and prognosis of heart failure. <i>Heart<\/i> 2000; <b>83<\/b>: 596-602.","DOI":"10.1136\/heart.83.5.596"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Pfeffer MA, McMurry JJ, Velazquez, <i>et al<\/i>: Varsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. <i>N Eng J Med<\/i> 2003; <b>349<\/b>: 1893-1906.","DOI":"10.1056\/NEJMoa032292"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14282-1"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(89)90227-0"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(85)91185-3"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Packer M, O'Conner CM, Ghali JK, <i>et al<\/i>: Effect of amlodipine on morbidity and mortality in severe chronic heart failure. <i>N Engl J Med<\/i> 1996; <b>335<\/b>: 1107-1114.","DOI":"10.1056\/NEJM199610103351504"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ghiadoni L, Magagna A, Versari D, <i>et al<\/i>: Different effect of antihypertensive drugs on conduit artery endothelial function. <i>Hypertension<\/i> 2003; <b>41<\/b>: 1281-1286.","DOI":"10.1161\/01.HYP.0000070956.57418.22"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Taddei S, Virdis A, Ghiadoni L, <i>et al<\/i>: Restoration of nitric availability after calcium antagonist treatment in essential hypertension. <i>Hypertension<\/i> 2001; <b>37<\/b>: 943-948.","DOI":"10.1161\/01.HYP.37.3.943"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Poole-Wilson PA, Lubsen J, Kirwan BA, <i>et al<\/i>: Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomized controlled trial. <i>Lancet<\/i> 2004; <b>364<\/b>: 849-857.","DOI":"10.1016\/S0140-6736(04)16980-8"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)11181-9"},{"key":"12","unstructured":"12. Hayashi T, Sohmiya K, Mori T, <i>et al<\/i>: Improvemant of left ventricular dysfunction by combination therapy with &beta;-blocker and angiotensin-II receptor antagonist in progressive heart failure. <i>J Am Coll Cardiol<\/i> 2002; <b>346B<\/b> (Suppl): 4078."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Nishida M, Hayashi T, Ieshima M, <i>et al<\/i>: Selective endothelin ET<sub>B<\/sub> receptor antagonist improves left ventricular function but exaggerates degeneration of cardiomyocytes in J2N-k hamsters. <i>Circ J<\/i> 2005; <b>69<\/b>: 107-113.","DOI":"10.1253\/circj.69.107"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(95)90116-7"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.1999.1744"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Matsuo T, Mori H, Nishimura Y, <i>et al<\/i>: Quantification of Immunohistochemistry using an image analyser: correlation with hormone concentrations in pituitary adenomas. <i>Histochem J<\/i> 1995; <b>27<\/b>: 989-996.","DOI":"10.1007\/BF02389689"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Rakusan K, Cicutti N, Maurin A, <i>et al<\/i>: The effect of treatment with low dose ACE inhibitor and\/or diuretic on coronary microvasculature in stroke-prone spontaneously hypertensive rats. <i>Microvasc Res<\/i> 2000; <b>59<\/b>: 243-254.","DOI":"10.1006\/mvre.1999.2224"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1016\/S1054-8807(99)00021-6"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Teerlink JR, Pfeffer JM, Pfeffer MA: Progressive ventricular remodeling in response to diffuse isoproterenol-induced myocardial necrosis in rats. <i>Circ Res<\/i> 1994; <b>75<\/b>: 105-113.","DOI":"10.1161\/01.RES.75.1.105"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. McMurray J, Chopra M, Abdullah I, <i>et al<\/i>: Evidence of oxidative stress in chronic heart failure in humans. <i>Eur Heart J<\/i> 1993; <b>14<\/b>: 1493-1498.","DOI":"10.1093\/eurheartj\/14.11.1493"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(98)00101-6"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.25.461"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.27.771"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1136\/heart.89.10.1236"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.25.117"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Berkels R, Egink G, Marsen TA, <i>et al<\/i>: Nifedipine increase endothelial nitric oxide bioavailability by antioxidative mechanisms. <i>Hypertension<\/i> 2001; <b>37<\/b>: 240-245.","DOI":"10.1161\/01.HYP.37.2.240"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Rostagno C, Abbate R, Gensini GF, <i>et al<\/i>: <i>In vitro<\/i> effects of two novel calcium antagonists (nitrendipine and nisoldipine) on intraplatelet calcium redistribution, platelet aggregation and thromboxane A2 formation: comparison with diltiazem, nifedipine and verapamil. <i>Thromb Res<\/i> 1991; <b>63<\/b>: 457-462.","DOI":"10.1016\/0049-3848(91)90232-L"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Berkels R, Klaus W, Boller M, <i>et al<\/i>: The calcium modulator nifedipine exerts its antiaggregatory property <i>via<\/i> a nitric oxide mediated process. <i>Thromb Haemost<\/i> 1994; <b>72<\/b>: 309-312.","DOI":"10.1055\/s-0038-1648858"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Knorr AM, Kazda S: Influence of nifedipine on experimental arteriosclerosis. <i>Cardiovasc Drugs Ther<\/i> 1990; <b>4<\/b>: 1027-1031.","DOI":"10.1007\/BF02018312"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Fleckenstein-Grun G, Thimm F, Czirfuzs A, <i>et al<\/i>: Experimental vasoprotection by calcium antagonists against calcium-mediated arteriosclerotic alterations. <i>J Cardiovasc Pharmacol<\/i> 1994; <b>24<\/b> (Suppl 2): S57-S84.","DOI":"10.1097\/00005344-199412001-00012"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Waters D, Lesperance J, Francetich M, <i>et al<\/i>: A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. <i>Circulation<\/i> 1990; <b>82<\/b>: 1940-1953.","DOI":"10.1161\/01.CIR.82.6.1940"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)91121-P"},{"key":"33","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.26.503"},{"key":"34","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000020755.56955.BF"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Haider KH, Ye L, Jang S, <i>et al<\/i>: Angiomyogenesis for cardiac repair using human myoblasts as carriers of human vascular endothelial growth factor. <i>J Mol Med<\/i> 2004; <b>82<\/b>: 539-549.","DOI":"10.1007\/s00109-004-0546-z"},{"key":"36","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000021924.02006.BA"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T12:33:45Z","timestamp":1683376425000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nature.com\/doifinder\/10.1291\/hypres.28.431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1291\/hypres.28.431","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005]]}}}